Paul Romesser

Dr. Paul Romesser

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2010 in Nature
Verified
Journal Article
Closed access
PDF file
RDR. Eric Davis
R. Eric Davis
VNVu N. Ngo
Vu N. Ngo
GLGeorg Lenz
Georg Lenz
PTPavel Tolar
Pavel Tolar
RYRyan M. Young
Ryan M. Young
LSLouis M. Staudt
Louis M. Staudt

22 December 2010 in Nature
Verified
Journal Article
Closed access
PDF file
VNVu N. Ngo
Vu N. Ngo
RYRyan M. Young
Ryan M. Young
RSRoland Schmitz
Roland Schmitz
SJSameer Jhavar
Sameer Jhavar
WXWenming Xiao
Wenming Xiao
LSLouis M. Staudt
Louis M. Staudt

21 December 2018 in Science
Verified
Journal Article
Closed access
PDF file
MRMarcus Ruscetti
Marcus Ruscetti
JLJosef Leibold
Josef Leibold
MBMatthew J. Bott
Matthew J. Bott
MFMyles Fennell
Myles Fennell
AKAmanda Kulick
Amanda Kulick
SLScott W. Lowe
Scott W. Lowe
Small molecules spark NK cell response: Immunotherapy is a powerful treatment for certain cancers. Yet for those patients that do not respond, simultaneous strategies that mobilize the immune system and directly target malignant cells may be more effective. Ruscetti et al. report that combining two clinically approved cancer drugs promoted immune surveillance and killing of KRAS-mutant lung tumors in mice (see the Perspective by Cornen and Vivier). The two small molecules—a mitogen-activated protein kinase inhibitor and a cyclin-dependent kinase 4/6 inhibitor—induced natural killer (NK) cell recruitment and elimination of senescent lung cancer cells, which did not occur when either agent was used alone. Science , this issue p. 1416 ; see also p. 1355

1 April 2021 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
PPPataje G Prasanna
Pataje G Prasanna
DCDeborah E Citrin
Deborah E Citrin
JHJeffrey Hildesheim
Jeffrey Hildesheim
MAMansoor M Ahmed
Mansoor M Ahmed
SVSundar Venkatachalam
Sundar Venkatachalam
CCC Norman Coleman
C Norman Coleman
Cellular senescence is an essential tumor suppressive mechanism that prevents the propagation of oncogenically activated, genetically unstable, and/or damaged cells. Induction of tumor cell senescence is also one of the underlying mechanisms by which cancer therapies exert antitumor activity. However, an increasing body of evidence from preclinical studies demonstrates that radiation and chemotherapy cause accumulation of senescent cells (SnCs) both in tumor and normal tissue. SnCs in tumors can, paradoxically, promote tumor relapse, metastasis, and resistance to therapy, in part, through expression of the senescence-associated secretory phenotype. In addition, SnCs in normal tissue can contribute to certain radiation- and chemotherapy-induced side effects. Because of its multiple roles, cellular senescence could serve as an important target in the fight against cancer. This commentary provides a summary of the discussion at the National Cancer Institute Workshop on Radiation, Senescence, and Cancer (August 10-11, 2020, National Cancer Institute, Bethesda, MD) regarding the current status of senescence research, heterogeneity of therapy-induced senescence, current status of senotherapeutics and molecular biomarkers, a concept of “one-two punch” cancer therapy (consisting of therapeutics to induce tumor cell senescence followed by selective clearance of SnCs), and its integration with personalized adaptive tumor therapy. It also identifies key knowledge gaps and outlines future directions in this emerging field to improve treatment outcomes for cancer patients.

1 February 2016 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
PRPaul Romesser
Paul Romesser
OCOren Cahlon
Oren Cahlon
ESEli Scher
Eli Scher
YZYing Zhou
Ying Zhou
SBSean L. Berry
Sean L. Berry
Nancy LeeNancy Lee
Nancy Lee

30 April 2009 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ASArthur L. Shaffer
Arthur L. Shaffer
NEN.C. Tolga Emre
N.C. Tolga Emre
PRPaul Romesser
Paul Romesser
LSLouis M. Staudt
Louis M. Staudt
IRF4, a member of the Interferon Regulatory Factor (IRF) family of transcription factors, is expressed in cells of the immune system, where it transduces signals from various receptors to activate or repress gene expression. IRF4 expression is a key regulator of several steps in lymphoid-, myeloid-, and dendritic-cell differentiation, including the differentiation of mature B cells into antibody-secreting plasma cells. IRF4 expression is also associated with many lymphoid malignancies, with recent evidence pointing to an essential role in multiple myeloma, a malignancy of plasma cells. Interference with IRF4 expression is lethal to multiple myeloma cells, irrespective of their genetic etiology, making IRF4 an “Achilles' heel” that may be exploited therapeutically.